TECHNOPHAGE, a biotechnology company headquartered in Lisbon, Portugal, announced today that the company has received authorization from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for TP-102, a bacteriophage cocktail for the treatment of infected chronic ulcers, namely diabetic foot infections. This clearance will enable TechnoPhage to initiate…

TECHNOPHAGE and SIMM, SHANGHAI INSTITUTE OF MATERIA MEDICA, a state-owned Institute administered and existing under the laws of the People’s Republic of China, have signed today a collaboration agreement for the joint development of a new pharmaceutical drug, leveraging the know-how and scientific complementarities of both entities in order to exploit new opportunities…